Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel in metastatic hormone-sensitive prostate cancer
NCT03343977Phase 2Withdrawn
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in prostate cancer (PCa). Planned start Feb 2018; status: withdrawn.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03343977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343977.